Indalo: Integral to fibrosis

How Indalo antagonizes multiple integrins to inhibit pro-fibrotic processes

Indalo Therapeutics Inc. is targeting the root causes in fibrosis by antagonizing multiple integrins simultaneously to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling.

Indalo President and CEO Robert Jacks said other fibrosis companies focus on the process by which integrins, particularly integrin αvβ6, activate transforming growth factor β (TGFβ), but do not address other integrin-mediated fibrotic processes, such as

Read the full 666 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE